Company profile
Cosyne Home - Cosyne Therapeutics
Transforming drug discovery through polymathic ai - Our mission is to develop cutting-edge therapeutics that improve the lives of patients
Financial period: 1 Mar 2024 to 28 Feb 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
SH08 | Transaction MzQ0MDQ4MjQ0N2FkaXF6a2N4 | Paper/PDF filed
Published 26 Oct 2024 06:17
SH01 | Transaction MzQ0MDI4MTA5N2FkaXF6a2N4
Published 21 Oct 2024 10:17
MA | Transaction MzQzOTA0MjAwMmFkaXF6a2N4 | Paper/PDF filed
Published 20 Oct 2024 06:18
RESOLUTIONS | Transaction WURERzAwNURhZGlxemtjeA | Paper/PDF filed
Published 20 Oct 2024 06:15
AP01 | Transaction MzQzODg5MjE3NGFkaXF6a2N4
Published 09 Oct 2024 08:16
Company registered at Companies House
1 Jan 2022 to 30 Jun 2023
**Background:** Gliomas are the commonest type of brain-cancer worldwide. They affect adults as well as children and cause **227,000 deaths** globally every year. Patients suffer with seizures, headaches, vomiting, blindness and personality-changes before **death follows in 95%** of high-grade cases. In addition to the terrible human cost, the burden of g...
